Quote Level 2 Charts News Trades Historical Financials Wiki Message Board

Oncosec Medical Incorporated (ONCS)

$ 0.441 ▲0.0015 (0.34%)
Volume: 834,736
Add ONCS To StreamerAdd ONCS To Streamer
Add ONCS To My StocksAdd ONCS To My Stocks
Add ONCS Price AlertAdd ONCS Price Alert
Bid Ask Last Traded Open Prev Close
0.44 0.447 3:53:32 PM EST 0.44 0.4395
Day's Range 52-Wk Range Avg Volume EPS P/E
0.43 - 0.448 0.36 - 0.97 1.08M N/A N/A
Market Cap Outstanding Float Dividend / Yield Ex-Div Date
108.86M 246.85M 229.45M N/A N/A
Short Interest Short % of Out Insider B/S Inst % Owned Exchange
1.16M 0.47 % N/A N/A USOTC
Support 2 Support 1 Pivot Price Resistance 1 Resistance 2
$ 0.4217 $ 0.4313 $ 0.4397 $ 0.4493 $ 0.4577
Link to Oncosec Medical Incorporated (QB) Stock Price

Oncosec Medical Incorporated (QB) Company Description


OncoSec Medical Incorporated is a biopharmaceutical company developing its proprietary DNA-based intratumoral cancer immunotherapy technology ? ImmunoPulse. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based agents that target tumor-induced immune subversion pathways. ImmunoPulse is a therapeutic approach that utilizes an electroporation delivery device in combination with DNA-encoded immune target modulators to treat cancer. Clinical studies of ImmunoPulse have demonstrated that the therapy is well-tolerated and preliminary evidence of anti-tumor activity has been observed, including the potential to initiate an immune response without the toxicities associated with systemic treatments. OncoSec Medical's lead program is evaluating ImmunoPulse for the treatment of metastatic melanoma. A Phase 2b study is in development to evaluate ImmunoPulse in combination with a checkpoint inhibitor, called anti-PD1 (pembrolizumab), for the treatment of metastatic melanoma and is being conducted in collaboration with several prominent academic medical centers. The company is also focused on identifying and developing new DNA-encoded proteins that target key pathways of tumor-induced immune subversion, investigating additional tumor indications, and evaluating other combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.

ONCS Intraday Stock Chart

1d 1m 3m 6m 1y 2y 5y


ONCS vs ETF alternatives
ETFsToday3mths1YrYTD
ONCS0.34%-15.14%-7.16%-17.11%
IJR-0.04%6.38%3.68%4.52%
EES0.08%5.92%0.62%1.73%
SCHA0.51%5.49%5.33%5.59%
VIOO0.29%6.76%4.57%5.40%
VB0.43%4.78%6.41%7.92%
DWAS0.03%6.54%-2.93%-0.82%
SAA-0.12%10.70%4.76%6.66%



Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.